The Global Point of Care Coagulation Testing Devices Market has witnessed continuous growth in the last few years and is projected to grow even further during the forecast period of 2024-2033. The assessment provides a 360° view and insights - outlining the key outcomes of the Point of Care Coagulation Testing Devices market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions.

Browse for Full Report at @ https://www.thebrainyinsights.com/report/point-of-care-coagulation-testing-devices-market-12648

Market size & segmentation (context)

• Global POC coagulation devices market: $1.88B (2024) → $3.23B (2032); North America led with ~$0.80B (2024).

• Another cut: $1.65B (2024) → $3.04B (2034), 6.3% CAGR; consumables ≈ $720M (2024), ~44% of revenue (single-use strips/cartridges = sticky recurring sales). 

Company references (devices & “values”)

• Roche — CoaguChek INR self-testing/professional meters (≈1-min INR result); Roche Group FY-2024 sales +7% (CER).

• Abbott Point of Care — i-STAT ACT (heparin monitoring in cath lab/OR); product page + recent FDA recall notice for i-STAT ACT Kaolin cartridges (Class II).

• Werfen — Hemochron Signature Elite (ACT/PT/aPTT at POC); ROTEM sigma viscoelastic POC system (FDA 510(k) cleared Jul-2022). Sales €2.2B (2024). 

• Haemonetics — TEG 6s viscoelastic POC platform; FDA clearance (FY-2024) for new TEG 6s Global Hemostasis-HN cartridge; hemostasis management revenue grew double-digits in FY-2024 commentary. 

• CoaguSense — Coag-Sense PT/INR professional & self-testing systems (FDA 510(k) K212779; prior review K183255).

• iLine Microsystems — microINR; FDA 510(k) 2023 adds Bluetooth-enabled microINR Link meter. 

Recent developments

• New POC viscoelastic assays: TEG 6s HN cartridge FDA-cleared (supports fully heparinized patients in CV surgery/liver Tx). ROTEM sigma FDA 510(k) for POC thromboelastometry.

• Connectivity/Cybersecurity: microINR adds Bluetooth; POC INR systems address FDA cybersecurity expectations in submissions.

• Quality/safety updates: i-STAT ACT Kaolin Class II recall (FDA).

•  

Key drivers

• Peri-operative bleeding management in CV surgery, trauma, liver Tx → demand for POC viscoelastic testing (reduces transfusions/blood loss in practice).

• Workflow & bed-side speed: rapid INR/ACT/PT/aPTT supports cath lab, ICU, ED, ambulatory surgery centers. 

• Recurring consumables economics (single-use strips/cartridges) and device miniaturization. 

Restraints

• Shift from warfarin to DOACs reduces the addressable pool for routine home INR testing. (Market commentary widely notes this dynamic; vendors lean into peri-op/acute use).

• Regulatory & QC burden (operator training, external QC, cybersecurity, recalls) can slow adoption.

Regional segmentation

• North America: largest share (2024) with strong hospital/ASC penetration and anticoagulation clinics. 

• Europe: broad adoption of ROTEM/TEG in peri-op pathways; active self-testing base for INR. 

• Asia-Pacific: fastest growth as ASCs and trauma networks expand and dry-reagent POC tech fits warm-climate logistics.

Emerging trends

• Viscoelastic testing (VET) at POC (TEG 6s, ROTEM sigma) becoming standard in complex surgeries/trauma. 

• Connected meters & RPM: Bluetooth-enabled INR (microINR Link) for clinic/home programs.

• Broad POC portfolios from majors (Roche POC ecosystem; Abbott i-STAT menu expansion, though not coag-specific). 

Top use cases

• Warfarin anticoagulation monitoring (INR) in clinic/home (CoaguChek, Coag-Sense, microINR). 

• Heparin monitoring (ACT) during PCI/cardiac surgery (i-STAT ACT, Hemochron).

• Peri-operative/trauma hemostasis guidance with VET (TEG/ROTEM). 

Major challenges

• Evidence & protocol integration outside tertiary centers; staff training for interpretation (VET curves/parameters). 

• Reimbursement variability for home INR programs and consumables in some markets. (General market constraint; varies by payer.)

• Supply/recall risks affecting cartridges and QC confidence (e.g., ACT Kaolin).

Attractive opportunities

• ASC & EMS deployment as devices miniaturize and deliver <5–10 min answers at bedside.

• Hospital blood-management programs quantifying transfusion savings → ROI for VET platforms and disposables.

• Connected home INR for selected warfarin populations (Bluetooth/RPM).

Key factors of market expansion

1. Installed-base growth + disposable pull-through (high-margin cartridges/strips).

2. Clinical guidelines & outcomes data supporting VET-guided transfusion algorithms.

3. Connectivity & cybersecurity-compliant designs (Bluetooth/RPM; FDA cyber guidance in 510(k)s).

4. Regional scaling in North America now; APAC catching up as ASCs/trauma networks expand. 

5. Portfolio breadth from majors (Roche, Abbott, Werfen, Haemonetics) enabling enterprise POC standardization.

If you want, I can convert this into a one-page slide or a table with each section and the cited company/product examples.